Ronovo Surgical Nabs $44M in Series B FinancingRonovo Surgical Nabs $44M in Series B Financing

Ronovo Surgical, a Shanghai-based medtech company, today announced the closing of its series B financing round, raising a total of $44 million to accelerate commercialization of its modular robotic system, the Carina Platform, on the Chinese market. Focused on its road to regulatory approval and commercialization for Carina in China, the financial round will support the company’s ability to expand into multiple specialties, “reducing learning curve and improving cost-effectiveness,” according to John Ma, CEO of Rovono Surgical, in the press release.

The series B round was co-led by Guolian Capital, INCE Capital, with participation from King Star Med LP and LongRiver Investments.

The company recently completed its multi-center, multi-specialty clinical trial for the surgical robotic device — including urology, gynecology, thoracic, and general surgery patients — ending with positive results as all procedures were completed without converting to laparoscopic, VATS, or open surgery.

"Taking Carina from concept design to completion of human clinical trial in three years, is the result of our clinical-driven approach toward engineering, practicality in design decisions and the remarkable dedication of our team,” said Ying Mao, CTO and COO of Ronovo Surgical, in the release.

The company expects to obtain NMPA regulatory approval and begin commercialization for Carina in early 2025.